#1C T G A T G A G A G T C A G A T G G G G A G G A T A A A A C T G A C G Jea 23andMe Investor Presentation A A C C G G A G C C T C G C C C G G A G A G A G A G G C C A T C T C A A T G G A C A#2Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe's businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this presentation, including statements regarding 23and Me's strategy, financial position, funding for continued operations, cash reserves, projected costs, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Except as required by law, 23andMe does not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. Use of Non-GAAP Financial Measures To supplement the 23andMe's unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"), this presentation also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that 23andMe defines as net income (loss) before net interest income (expense), net other income (expense), changes in fair value of warrant liabilities, income tax benefit, depreciation and amortization of fixed assets, amortization of internal use software, amortization of acquired intangible assets, goodwill and intangible assets impairment, non-cash stock-based compensation expense, acquisition-related costs, and expenses related to restructuring and other charges, if applicable, for the period. 23andMe has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this presentation. Adjusted EBITDA is a key measure used by 23andMe's management and the board of directors to understand and evaluate operating performance and trends, to prepare and approve 23andMe's annual budget and to develop short- and long-term operating plans. 23andMe provides Adjusted EBITDA because 23andMe believes it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry and it facilitates comparisons on a consistent basis across reporting periods. Further, 23andMe believes it is helpful in highlighting trends in its operating results because it excludes items that are not indicative of 23and Me's core operating performance. In particular, 23andMe believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of 23andMe's business. Accordingly, 23andMe believes that Adjusted EBITDA provides useful information in understanding and evaluating operating results in the same manner as 23andMe's management and board of directors. In evaluating Adjusted EBITDA, you should be aware that in the future 23andMe will incur expenses similar to the adjustments in this presentation. 23andMe's presentation of Adjusted EBITDA should not be construed as an inference that future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. When evaluating 23andMe's performance, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss and other GAAP results. Intellectual Property All rights to the trademarks, copyrights, logos and other intellectual property listed herein belong to their respective owners 23andMe's use thereof does not imply an affiliation with, or endorsement by the owners of such trademarks, copyrights, logos and other intellectual property. Solely for convenience, trademarks and trade names referred to in this Presentation may appear with the Ⓡor TM symbols, but such references are not intended to indicate, in any way, that such names and logos are trademarks or registered trademarks of 23andMe. Industry and Market Data This Presentation relies on and refers to certain information and statistics based on 23andMe's management's estimates, and/or obtained from third party sources which it believes to be reliable. 23andMe has not independently verified the accuracy or completeness of any such third party information. 23and Me Copyright © 2023 23andMe, Inc. 2#3G G G 1 с T 23andMe Mission: To Help People Access, Understand, and Benefit from the Human Genome с с#4The Problem: Today's Healthcare System Has Only a Small Impact on Our Health and Well Being 1. Schroeder, SA. (2007). We Can Do Better - Improving the Health of the American People. NEJM. 357:1221-8. Impact of Different Factors on Risk of Premature Death¹ Social & Environmental Factors 20% Individual Behavior 40% Health and Well-being Health Care 10% Genetics 30%#5Today's Healthcare System is Dysfunctional "Of course our system isn't about healthcare, it's about maximizing revenue for a whole bunch of different players that have nothing to do with what's good for patients." Elisabeth Rosenthal (Editor-in-Chief, Kaiser Health News) ¹ JAMA, "Waste in the US Health Care System" (2019). 2 Redpoint Global / Dynata survey of over 1,000 U.S. consumers (2020). 3 Gallup, "Americans' Views of U.S. Business and Industry Sectors" (2020). 4 PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). 25% U.S. healthcare spending is waste 1 75%* Consumers wish their healthcare experience was more personalized 3 2 Copyright © 2023 23and Me, Inc. -15 The Net Promoter Score (NPS) Americans gave the pharmaceutical industry 4 <12%* Probability of success for a drug to be approved, taking ~10 years and costing $2.6B to develop 23andMe 5#6G G 2 с T 23andMe Revolutionizing the Diagnosis, Prevention and Treatment of Human Disease с с A#7G G Unlocking the Genetic Code Creates the Opportunity to Revolutionize the Diagnosis, Prevention and Treatment of Human Disease C G C Cracking the code... ACGT ...is a data problem, a very big data problem We are all 99.5% genetically alike 3 billion base pairs long Copyright © 2023 23and Me, Inc. 23andMe 7#8Media Commerce Hospitality >>> Healthcare Transportation >>> Uber >>> ► YouTube >> amazon airbnb X 23andMe Consumer Scale and Empowerment is the Key to Disrupting Healthcare "Healthcare cannot change from within, it will need an outside force to change it, and that force will be our customers." Anne Wojcicki#923andMe The Size and Scale of 23and Me Enables Rapid, Novel Discoveries Welcome to you 1 Genotyped customers as of December 31, 2022. saliva collection kit 23andMe REGENERON MILLION VETERAN PROGRAM UK BIOBANK DECODE GENETICS FINNGEN ALL OF US GENOMICS ENGLAND ~2M+ 900,000+ 500,000 500,000 473,000+ 413,000+ 100,000 Copyright © 2023 23and Me, Inc. 23andMe 13.6M¹ 9#10We Pioneered Digital DTC Healthcare to Empower Customers With Affordable, Direct Access ¹ See FDA De Novo Authorizations 140044, 160026, 170046 and 180028 and FDA 510K Clearances K182784 and K193492. 8 FDA Authorizations/ Clearances TIME MAGAZINE INVENTION OF THE YEAR 1. The Retail DNA Test By Anita Hamilton Wednesday, Oct. 29, 2008 Best Inventions of 2008 > From a genetic testing service to an invisibility cloak to an ingenious public bike system to the world's first moving skyscraper - here are TIME's picks for the top innovations of 2008 Proven accuracy (99% NPV/PPV) and accessibility¹ 2015 2016 2017 2018 2019 Carrier Status (inherited conditions) GHR (genetic health risk) BRCA (breast and ovarian cancer) PGt (pharmacogenetic metabolism) MUTYH (colorectal cancer) 2020 PGt (pharmacogenetic drug response) 2022 HOXB13 (prostate cancer) 2022 Simvastatin (cholesterol PGt)#11>90% of 23andMe+ members receive a report with meaningful genetic results 18,000+ Customers with an increased risk for Chronic Kidney Disease 8,000+ 12,000+ Customers with a tested BRCA1 / BRCA2 variant Customers with Hypercholesterolemia (FH) variants Note: Estimates based on prevalence of variants in 23andMe's Database as of September 30, 2022. Providing Customers With Key, Actionable Insights "Like me, there are many women who have slipped through the cracks of our current medical screening system, either because they don't have a family history of breast or ovarian cancer. Or they do not know that they have Ashkenazi Jewish ancestry. In my case, even though I know I have Ashkenazi ancestry, that wasn't enough to prompt my doctor to consider screening. So there are many women walking around with this risk, who, like me, would have never known of their own risk but for this test from 23andMe." 23andMe customer who discovered she had a BRCA1 mutation#12Genetic Data Helps Drive Behavior Change Based on 2019 online survey, designed by 23andMe and M/A/R/C Research, of 1,046 23andMe Health + Ancestry customers. 76% Report taking a positive health action¹ Eat healthier Set future goals to be healthier Adopt a healthier lifestyle in general Exercise more Get more rest / sleep Stop drinking / drink less Stop smoking / smoke less 7% 16% Copyright © 2023 23and Me, Inc. 45% 42% 23andMe 51% 50% 55% 12#13Opportunity for Personalized Healthcare at Scale Practice of Medicine Today Reactive - no customization until symptomatic !!!!! P 23andMe+ Proactive - truly individualized from the very beginning >> >>> >> Copyright © 2023 23andMe, Inc. 23andMe 13#14G G 3 с с Transforming Healthcare with Genetic Health Services at Scale T с с C#15Problems we are solving Prevention is not a focus The majority of people living in the United States don't think about health until it's too late. 2 Health is not accessible Healthcare is elusive to many people and it is often gated by affordability, geography, cultural affinity, and overly complex systems. 3 Health is not personal Most healthcare today takes a generic approach, often missing the full context to people's lives and failing to deliver a path to their wellbeing. Copyright © 2023 23and Me, Inc. 23andMe 15#16What are Genetic Health Services? Health Predispositions Identify risks, implement targeted prevention, monitoring, and management Wellness Targeted to help you feel your best Pharmacogenetics Therapeutics that work best for you 23andMe Welcome to you + salva collection sit Holli || Copyright © 2023 23and Me, Inc. 23andMe 16#1712² Future of 23and Me: Fully Integrated Genetic Health Services 23andMe® Genetic Health Evaluation Telehealth Services Lab Tests Precision Prescribing Using Pharmacogenetics All connected within a single technology platform Available in all 50 states Copyright © 2023 23and Me, Inc. ←|→ Long-term Engagement 23andMe 17#18First Step: Genetic Health Evaluation A dynamic, longitudinal service that combines your health data (genetic, medical, lifestyle, environmental, wearables, etc.) with your interests and goals, and delivers a personalized health & wellness plan with interesting, engaging, recommendations. INPUTS Health profile DNA & clinical tests Connected & self-reported data Genetic Health Evaluation OUTPUTS Health plan & recommendations Insights, education & resources Feedback Copyright © 2023 23andMe, Inc. 23andMe 18#19Next Step: Implementing a Genetically Informed, Personalized Health & Wellness Plan Consultation with a clinician to develop a personalized health & wellness plan that could include additional labs, treatment options and lifestyle changes Copyright © 2023 23and Me, Inc. 23andMe 19#20Health Predispositions¹ 30+ Including: Type 2 Diabetes (Powered by 23andMe Research) Coronary Artery Disease 23 andMe+ Uterine Fibroids 23andMe+ Migraine 23 and Me+ MUTYH-Associated Polyposis BRCA1/BRCA2 (selected variants) Type 2 Diabetes YOUR RESULT Your genetics are associated with a typical likelihood. Based on your: XXX Genetics Age 37% 23andMe Personal Genome Service (PGS) The First and Only Multi-Disease DTC Personal Genome Service that Includes FDA-Authorized Reports and Provides Personalized Genetic Insights and Tools 4 Ethnicity Wellness 2 10 Including: Muscle Composition Genetic Weight Alcohol Flush Reaction Saturated Fat and Weight Sleep Movement Dog & Cat Allergies 23andMe+ Genetic Weight YOUR RESULT Your genes predispose you to weigh about 7% less than average. Average 142 lbs Carrier Status 40+ Including: Cystic Fibrosis Sickle Cell Anemia Familial Hyperinsulinism (ABCC8-Related) Tay-Sachs Disease Glycogen Storage Disease (Type 1a) Chromosome Tay-Sachs Disease YOUR RESULT You do not have the variants we tested. 0 variants detected in the HEXA gene 1. Includes FDA Authorized Genetic Health Risk Reports and Wellness Reports for Genetic Likelihood Powered by 23andMe Research. 2. Wellness information does not require FDA Authorization. Pharmacogenetics 3 Including: SLC01B1 Drug Transport CYP2C19 Drug Metabolism .e.g., citalopram and clopidogrel DPYD Drug Metabolism Copyright © 2023 23andMe, Inc. Pharmacogenetics Genetic variants may influence how you process medications. YOUR RESULTS CYP2C19 Drug Metabolism LIKELY NORMAL METABOLIZER DPYD Drug Metabolism LIKELY NORMAL METABOLIZER SLCO1B1 Drug Transport LIKELY NORMAL FUNCTION 8 FDA Authorizations/ Clearances Print summary 23andMe+ 23andMe 20#21Unique to 23and Me: FDA-Authorized Pharmacogenetics Reports 3 reports and 3 medication insights that look at genetic variants that influence how a person responds or processes certain medications (FDA-cleared) SLC01B1 Drug Transport CYP2C19 Drug Metabolism DPYD Drug Metabolism Statin-induced myopathy Clopidogrel, citalopram response Fluoropyrimidine toxicity Copyright © 2023 23and Me, Inc. 23andMe 21#22woll Long-term Engagement with Customers Educate General education about health risks and preventative measures in context of overall health Passive Data Monitoring Monitor health data and recommend earlier testing based on risk assessment Follow-up Testing Schedule follow-up labs as needed based on risks identified in genetic health evaluation olli Automated Insights Tailored recommendations based on individual health data Clinician Consultation Option to consult with Lemonaid clinician as needed Cascade Testing Potential for education & testing of family members as needed Copyright © 2023 23and Me, Inc. 23and Me 22#23A Bold predictions for human genomics by 2030 CC The regular use of genomic information will have transitioned from boutique to mainstream in all clinical settings, making genomic testing as routine as complete blood counts." Strategic vision for improving human health at the forefront of genomics National Human Genome Research Institute Nature, October 28, 2020 C A Copyright © 2023 23andMe, Inc. 23and Me 23#24G G 4 C с Transforming the Development of Therapeutics With the 23andMe Database T с с G C T#25Opportunities to collaborate with 23andMe Target - Drug Discovery - Drug Development Collaborations Human genetics-driven target discovery Target Discovery Target val Lead opt IND-enabling Deeply phenotyped cohorts (e.g., Parkinson's) Phase 1 Portfolio validation Clinical trial recruitment based on genetics Phase 2 Phase 3 Marketing Genetics-driven disease awareness, cascade screening, and confirmatory testing Copyright © 2023 23and Me, Inc. 23andMe 25#26An Experienced Biopharma Leadership Team 100+ years of experience: Genentech, Amgen, Gilead, GSK Loxo, Achaogen, ProNeurotech, National Cancer Institute, Albert Einstein College of Medicine From Left to Right: Adam Auton Monica Viziano Jennifer Low Bill Richards Kenneth Hillan Joe Arron Vice President, Human Genetics Vice President, Portfolio Strategy and AM Head of Therapeutics Development Vice President, Target and Drug Discovery Chief Therapeutics Officer Chief Scientific Officer, Therapeutics https://www.23andme.com/therapeutics/ 6 2aanthe#27Unique 23andMe genetic and phenotypic data platform and insights Genetics based drug discovery and development Ability to recontact customers and to conduct real-time research at scale ● Advanced statistical and computational modeling 23andMe Therapeutics Core Capabilities Fully operational biopharma capabilities ● ● In vitro and in vivo translational research laboratories Antibody and protein engineering CMC, analytics, bio-analytics and quality assurance Non-clinical and early phase clinical development Track record of successful target and drug candidate discovery; an experienced drug development team Ability to move quickly from target validation to the clinic Extensive experience in portfolio and alliance management Focus on delivering value for our partners Holli Copyright © 2023 23and Me, Inc. XX 23and Me 27#28Potential to use Genetics to More Efficiently Develop Novel Therapeutics by "Power, Need, and Speed" 1. IND Investigational New Drug Application. fdareview.org, "The Drug Development and Approval Process" (2020). 2. Probability of success for a drug to be approved is estimated to be <12%. 3. PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). Drug Development is Inefficient 7 years average time-to-IND¹ $2.6B average cost of drug development³ Copyright © 2023 23and Me, Inc. ~90% failure rate², 3 23andMe 28#29Our Scale Enables Real-Time Research Across Multiple Disease Areas Including (numbers below represent the number of research participants with the condition indicated) Example Phenotype Asthma Type 1/ Type 2 diabetes Irritable Bowel Syndrome Osteoarthritis Solid Tumors Basal Cell Squamous Cell Melanoma Breast Colorectal Thyroid Hematologic Cancers NHL Leukemia Retinal Diseases AMD Glaucoma Rare Diseases Sarcoidosis Idiopathic Pulmonary Fibrosis Number of Cases¹ 1.2M 40K / 413k 742k 857k > 1M 412k 222k 127k 119k 25k 27k 18k 14k 106k 193k 8.9k 5k ¹ As of December, 2022. 2 MedRXiv Sept. 7, 2020 (10.1101/2020.09.04.20188318). 3 Nature Genetics, 53, pages 801-808 (2021) > 1.4M COVID-19 study participants COVID-19 Research March 16 2020 April 6 2020 June 8 2020 Sept. 7 2020 750k Consumers participated in the COVID-19 study in the first 90 days April 22 2021 Kicked Off Study Launched Study Preliminary Findings Posted Preprint Findings² Published in Journal³ Re-contactable Customers Participate in Health Research 29#30Genome-Wide Association Studies (GWAS) GWAS is a statistical analysis of Single Nucleotide Polymorphisms (SNPs), looking to identify differences in frequency between disease cases and controls. SNPs linked with disease will be found at different frequencies in cases versus controls. Association is represented by the level of statistical significance (p-value) of the SNP frequency difference. SNPs can be tested across the genome and mapped to specific regions. Single Nucleotide Polymorphism (SNP) GGCCAGCTGGACGAGG GGCCAGCTGGAT GAGG - log10 (pvalue) 200- 100 - 50 20 10 5 2 4 102.2 5 102.4 6 FL2013 7 102.6 8 9 GAMI+ MAL 10 Cases 11 12 11123923 SLOGA LIMA MA4772 14 SLOBA 103:2 16 THEMI 103.4 Copyright © 2023 23and Me, Inc. 18 20 22 X Controls 23andMe 30#31Example: Number of Osteoarthritis GWAS¹ hits dramatically increase as database grows 2016 2017 2021 -log₁0(pvalue) -logo(pvalue) log₁0 (pvalue) 12- 10- 15- 40 Size and Scale Accelerate Target Discovery 20 1 GWAS: Genome-Wide Association Study. 3 4 1969 5 6 9 10 11 12 Chromosome 7 8 9 10 11 12 Chromosome 7 8 9 10 11 12 Chromosome 14 14 16 18 20 22 X 16 18 20 22 X 16 18 20 22 X Number of independent hits p<5e-8 New programs are identified through GWAS¹ hits, which increase as size of database grows 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0 2015 2016 2017 2018 Copyright © 2023 23and Me, Inc. 2019 2020 23andMe 31#32Hundreds of Distinct Clinical Phenotypes Across Major and Rare Diseases musculoskeletal P wa se tre Mycke tact Fachpo edhe cardiovascular oc Festy gra w wyma av va P eyes Pheno LEO. huar schoe FW. d costune che sty acom da po typ pm.angle 187 ping Orthopedic Lost Cardiovascular --- Ophthalmology Se-Se-New Lost Phenotype NAFLD (Non-Alcoholic Fatty Liver Disease) neurological VINOW G Qay M B negen food p midcentive h gastrointestinal pend end of a ww os dvertica padd P D C metabolic M 1 ge Joby He reve GR . k bath He hims Neurology PHET NE G.I. osalllliluill mmm mmm Metabolic Disease Cases Controls 48048 2517644 immune Platyp the q autoimmune Phenotype upareats o c nh h pod up Ap pamiquers polymyalgia rhuuto Mola po pl ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬‒‒‒‒‒‒ do arbits sydne infection Preotype apping toyota Allergy Autoimmunity Se-ate-own Infectious Disease THIEURE Hits New Lost 104 44 2 cancer F Ba on.com c It cance colon H om b 2 2 www.cm w jačka boost za and blood Paytre LICH art tomto 2140 wa ch re c ottags tra Peny www.y www.hay iphetmcme polahs Iyout D na ch pompon www.top w blood b endocrine D ch agency Copyright © 2023 23andMe, Inc. Cancer Gas Co Hematology Hulintindihalli www. ---- Endocrine wie auch 11 Sede Indana PEPER address WEERGERBRE ALCAL meller kan d 23andMe 32#331 40 PEMAS MOLT 1095 10974910 1.1 Genetic Association of the TSLP Signalling Pathway With Asthma 110 UN POCOLO 110.5 Position on chrs (Mb) 113077425 Cad10.20 TORR THE MARSAS 19 ROMANA Pon(M) VAADE M C Poston chr( M +++ 13. 65 #1837253 POL *SLAPSAS 1115 7 100 -80 -TSLPR I Cell membrane JAK2 TSLP STAT5 IL-7Ra JAK1 Proinflammatory signaling I I 1 1 647 PLACCALPAY SPERZ 1512687352 35.5 358 Pastion on ches (M) 64.9 - CA 12409033 3+ M UT CAPS MAGLU me JAKT COM PSAC 42.5 05 TUB CORD IN www. ww ONI +THE+BON gra 36 COPERCAL AARS RUNDO IATA UCITIAL RAD 30.1 M 052 TENTA cocam SAY APLAD 435 2892 TSLP is a well-known cytokine with a role in maintaining immune homeostasis and regulating inflammatory responses at mucosal barriers. The TSLP signaling pathway is an attractive therapeutic target. e.g. Tezepelumab, a TSLP-blocking monoclonal antibody for treatment of asthma. Our genetic data shows that multiple genes within the TSLP pathway associate strongly with asthma. Copyright © 2023 23and Me, Inc. 23andMe 33#34Breadth of Phenotyping Provides Deeper Genetic Understanding Beyond Single Diseases PheWAS = Phenotype Wide Association Study Every SNP in the genome can be interrogated at >1,000 medically related phenotypes. Besides the role of a gene in a disease of interest, we can use genetics to learn potential indication expansions or possible unwanted toxicities. For TSLP, PheWAS indicates lack of effect in eczema but also highlights potential indication expansion in a rare disease. TSLP PheWAS Asthma - crohns- eczema - hashimotos- multiple sclerosis - psoriasis- psoriatic_arthritis - Rare disease A- rhinitis. tld- ulcerative colitis TSLP GWAS signal 1 TSLP GWAS signal 2 TSLP GWAS signal 3 Copyright © 2023 23and Me, Inc. log(OR) 0.2 0.0 -0.2 23andMe 34#351. 2. A Research and Development Pipeline Covering Multiple Therapeutic Areas Immuno-oncology GSK'608¹ (CD96) EARLY-STAGE THERAPEUTIC AREAS (multiple programs in each area) Immuno-oncology Immunology 23ME'610 (CD200R1) Cardiovascular/ Metabolic Neurology Discovery Preclinical Phase 1 50+ programs² GSK is solely responsible for the development of GSK6097608 (GSK'608) in later-stage clinical trials. Subject to its successful commercialization, 23andMe is eligible to earn tiered worldwide royalties up to the low double digits. The 50+ programs in the combined therapeutic areas include 100% owned and royalty interest targets as well as those in collaborations. The majority of the programs are in collaboration with GSK. Note: As of March 31, 2022 Phase 2 GSK 23andMe Copyright © 2023 23andMe, Inc. 23andMe 35#36>>> >>> >>> >>> Systematic, Scalable Research Platform Yields Novel Drug Targets Phenotypic Data Genetic Data 10,000s of Genome-Wide Association Study (GWAS) Hits Determine Disease Associated Genes and Directionality Translational Research to Understand Mechanism Identifying Druggable Targets Phenome-Wide Association Studies (PheWAS) Reveal Additional Indications and Potential Safety Concerns Assessment of Unmet Need and Competitive Landscape Best Drug Targets Wet lab validated targets progress through standard stages of research toward the selection of preclinical lead molecules and clinical development 23andMe's database yields thousands of GWAS hits Advanced biology and medicinal chemistry guide design of optimal compounds from initial targets Phenotypic breadth provides unique ability to uncover potential safety issues or possible indication expansions Copyright © 2023 23andMe, Inc. 23andMe 36#3723andMe Immuno-oncology (I/O) Programs#38Our I/O Programs Were Identified With ML and AI Applied to Our Proprietary I/O Genetic Signature Large I/O market with $60B in 2021 sales 2021 sales of leading checkpoint inhibitors KEYTRUDA $17.2B OPDIVO YERVOY $7.5B $2.0B 23andMe's proprietary I/O genetic signature developed with ML which also identifies marketed I/O drugs I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes tonsillectomy- 11d- anti tn alpha or dmards- juvenile ttd- igb.dry skin froquancy- iodine treatment ever- hypothyroidism- hyperthyroidism hashimotos grines vitiago- iqb.dandruff frequency- celiac HLA all psoriasis rheumatoid arthrite look meds anti inf_alpha- thyroid removed- immunodeficiency squamous cell carcinoma - basal cell carcinoma actinic keratosis- non melanoma skin cancer- any skin cancer- Autoimmune Cancer We discovered additional targets that have a similar genetic I/O signature CD200R1 (23ME'610) CD96 (GSK'608) + others Copyright © 2023 23and Me, Inc. 23andMe 38#3923ME'610 Targeting CD200R1#40CD200R1 was Identified as a Promising Anti-Cancer Drug Target with 23andMe's Proprietary Immuno-oncology (I/O) Genetic Signature Immune and autoimmune phenotypes Cancer phenotypes Identified novel immuno-oncology signature around CTLA4. tonsillectomy - tld- anti tnf_alpha_or_dmards - juvenile_t1d- iqb.dry_skin_frequency - iodine treatment_ever - hypothyroidism - hyperthyroidism - hashimotos- graves - vitiligo- iqb.dandruff frequency- celiac HLA_all- signed log(p) psoriasis- rheumatoid arthritis - took_meds_anti_tnf_alpha- thyroid_removed- immunodeficiency - squamous_cell_carcinoma - basal cell carcinoma - actinic_keratosis - non_melanoma_skin_cancer- any_skin_cancer - -10 -5 0 5 10 Genetic Variant in CTLA4 linked with multiple phenotypes in the 23andMe database CD200R1 pathway identified as a critical immune checkpoint with our I/O genetic signature CD200R1 Receptor Immune I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes Cancer Cancer Immune CD200 Ligand DOK2 Protein Immune Cancer signed log(p) -10 -5 0 5 10 We discovered that 3 components of the signaling pathway for CD200R1 have a similar genetic signature to other I/O drugs Copyright © 2023 23andMe, Inc. 23andMe 40#41CD200R1 is an Immune Checkpoint CD200R1 is an inhibitory receptor expressed on T-cells and myeloid cells CD200 is the only known ligand for CD200R1 in humans and is highly expressed in certain cancers Binding of CD200 to C200R1 decreases the ability of T-cells to recognize and kill cancer cells Several viruses have co-opted CD200 analogues to suppress and evade the host immune response References: J Virol 2012;86:6246, J Virol 2004;78:7667, J Immunol 2005;175:4441, Structure 2013;21:820, JCI Insight 2018;3:e96836 00 Tumor cell CD200:CD200R1 Signaling CD200 Reduced antitumor immune response DO CD200R1 Copyright © 2023 23and Me, Inc. Immune cell PPP RasGAP DOK2 ERA FRED AND Ras Akt 23andMe 41#4223ME-00610 (23ME'610) Binds with High Affinity to CD200R1 and Inhibits Immunosuppressive Signaling 23ME '610 is a fully humanized, effectorless, IgG1 antibody against human CD200R1 23ME '610 binds CD200R1 with high affinity (K < 0.1 nM) 23ME '610 blocks CD200 ligand binding to CD200R1, resulting in inhibition of immunosuppressive signaling The restoration of T-cell activity by 23ME '610 was demonstrated using in vitro models of the tumor microenvironment No adverse effects of blocking CD200R1 have been observed in nonclinical toxicology studies *CD200-expressing cell types include tumor, stroma and endothelial IFN, interferon; IL, interleukin 23ME'610 Activates T-cell Function by Blocking the CD200R1 Checkpoint Tumor cell* Tumor cell* CD200 +23ME-00610 CD200R1 Copyright © 2023 23andMe, Inc. T cell IFNY ↓LL-2 Antitumor cytotoxicity T cell ↑ IFN TIL-2 ↑ Antitumor cytotoxicity 23andMe 42#43CD200R1 is expressed on tumor-infiltrating from The Cancer Genome Atlas (TCGA) CD200R1 expression (using RNAseq data from TCGA) is correlated with several immune cell markers: CD4, CD8, CD45 (shown), and CD11b CD200R1 is co-expressed with antigens or markers that are expressed on lymphocytes seen in most cancer types Log10 (CPM+0.05) of CD45 2.5- CD200R1 correlation with CD45 (hematopoietic cells)¹ 2.0 1.5- lymphocytes (TILs) 1.0- 0.5 rho = 0.86 KIRC -1.0 -0.5 0.5 1.0 1.5 Log (CPM+0.05) of CD200R1 1. Clear cell renal carcinoma (KIRC) is shown and was chosen because it had high immune infiltration in the TCGA dataset Copyright © 2023 23and Me, Inc. 23andMe 43#44Inhibition of CD200R1 has the potential to address resistance to anti-PD1 therapies Fold Change Relative to Control Blocking the CD200R1 pathway enhanced IFNy production from SEB-stimulated PBMCs compared to isotype control and anti-PD1 in the majority of samples tested * * Endometrial 1 Endometrial 2 * Ovarian 1 Interferon-y * Lung * Melanoma Pancreatic Endometrial 3 PBMCs from each respective patient were incubated with 100 nM of 23ME-00610, anti-PD-1, or isotype control. Cells were stimulated with SEB. IFNY levels were determined by enzyme-linked immunosorbent assay. Mean biologic triplicates were normalized to isotype control. *P <0.05. 23ME '610 Isotype Control anti-PD1 Prostate Colorectal Copyright © 2023 23andMe, Inc. PBMC, peripheral blood mononuclear cell; PD-1, programmed death-1; SEB, staphylococcal enterotoxin B. 23andMe 44#451 Phase 1 Phase 1/2a Study of 23ME'610 in Patients with Locally Advanced or Metastatic Solid Malignancies Patients with locally advanced, unresectable or metastatic solid tumors that have progressed after or are inappropriate for standard therapy Study Design Y Openlabel Part A (n = 26) Monotherapy Dose Escalation (IV Infusion Q3W) Accelerated Titration 3+3 Cohorts RP2D / MTD x Non- Randomized Multi-center Part B (n = 75) (~15/cohort) Neuroendocrine Cancers Small Cell Lung Cancer Ovarian Cancer Renal Clear Cell Cancer MSI-H & TMB-H Cancers Adolescent Cancers Primary Objectives Part A: Safety (DLTS, AES) Part B: Efficacy (ORR) Secondary and Exploratory Efficacy (ORR [RECIST and iRECIST]), DOR, PFS, OS) and Safety > Pharmacokinetics Pharmacodynamic biomarkers Abbreviations: AEs: Adverse Events; DLT: Dose limiting toxicity; DOR: duration of response; IV: intravenous; ORR: Objective Response Rate; OS: Overall Survival; PFS: Progression Free Survival; Q3W: every three weeks; RECIST: Response Evaluation Criteria in Solid Tumors; RP2D: Recommended Phase 2 Dose Copyright © 2023 23and Me, Inc. 23andMe 45#4623ME'610 Targeting CD200R1: A Genetically-Validated Approach to Anti-Cancer Therapy CD200R1 is an immune checkpoint with a strong I/O signature in three components of the pathway. • 23ME-00610 is a high-affinity, first-in-class, anti-CD200R1 antibody with immune-activating properties, including: O Prevention of CD200-mediated suppression of chronically stimulated T cells O Enhancement of cytokine secretion from peripheral blood mononuclear cells (PBMCs) isolated from cancer patients O o Augmentation of PBMC-mediated tumor cell killing CD200R1 expression was observed on tumor infiltrating lymphocytes from The Cancer Genome Atlas, suggesting that this pathway contributes to an immunosuppressive tumor microenvironment. CD200R1 was also expressed in immune checkpoint inhibitor non-responders, indicating that inhibition of the CD200R1 immune checkpoint has the potential to address resistance to anti-PD-1 and anti-CTLA4 therapies¹. Phase 2a portion of the study study will evaluate five tumor indication-specific expansion cohorts and a cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies. 1. Data presented in poster at 2022 American Association for Cancer Research (AACR) annual meeting.